PharmiWeb.com - Global Pharma News & Resources

Today Stories

World Glaucoma Week is a global initiative of the World Glaucoma Association (WGA) in order to raise awareness on glaucoma. Through a series of engaging worldwide activities, patients, eye-care providers, health officials and the general public are invited to contribute to sight preservation. The goal is to alert everyone to have regular eye (and optic nerve) checks in order to detect glaucoma as early as possible. World Glaucoma Week 2021 is taking place from 7th - 13th March. Think global, act local Each year, the World Glaucoma Week adopts a common theme, which is adapted to local conditions, and yet unifies our efforts. To be effective, community awareness projects need to be relevant for the general population. That means they need to be based locally and thus, rely on individuals in…
ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA immunotherapies NV ("eTheRNA"), a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its ground-breaking TriMix technology, have agreed to collaborate on the development of vaccine candidates for infectious diseases. It is anticipated that by combining ConserV's and eTheRNA's technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses. This collaboration brings together ConserV's expertise in identifying broadly-protective antigens and eTheRNA's TriMix immunostimulatory mRNA technology and novel lipid nanopartic…
ProPharma Group, a portfolio company of Odyssey Investment Partners, announces the acquisition of Diamond Pharma Services. Diamond Pharma Services provides regulatory affairs, pharmacovigilance, and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licenses throughout all stages of a product’s lifecycle. “We are excited to welcome Diamond Pharma Services into the ProPharma Group family,” said Dawn Sherman, ProPharma Group’s CEO. “This acquisition further solidifies ProPharma Group’s position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services. With our mission and higher purpose of improving the health and safety of patients, we are focused on deliv…
Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, today announces that its SYNE-COVTM machine learning algorithm for COVID risk prediction has achieved regulatory approval for use in the UK. About SYNE-COV SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID infection.  The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust This is the first algor…
The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim’s research into approaches with first in class potential for the treatment of obesity  Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemis…
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company's management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies. "John will be an important addition to 4D pharma's management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expertise as a CFO of several publicly traded life sciences companies will be critical as we further grow our company and global footprint," said Dunca…
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “Pandion has applied its TALON technology to develop a robust pipeline of candidates desig…
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders. All customers will benefit from increased functional, geographic and therapeutic scale as well as expansive healthcare technology innovation. The combination will address the growing market need for de-centralised and hybrid trial solutions from a differentiated combination of mobile and connected health platforms, a global site network, home health services and wearables expertise. The combined business will be no. 1 or 2 in key clinical market segments and have formal strategic partnerships with a majority of the top 20 biopharma comp…
What? Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. The campaign targets primarily the general public and also seeks to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases. Why? Building awareness of rare diseases is so important because 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Rare Disease Day improves knowledge amongst the general public of rare diseases while enc…
Transformative partnership reunites University of Toronto and Novo Nordisk to commemorate the 100th anniversary of the discovery of insulin and jumpstart a new era in precision public health. Novo Nordisk A/S and the University of Toronto (U of T) today announced a DKK 200 million (CAD 40 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new ways to support healthier urban populations and will draw on U of T’s leading expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic diseases. Based at U of T Mississauga, the new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and University of Toronto Missi…
Almac Sciences, a member of the Almac Group, has completed a £5 million investment in a new two-storey centre for biocatalysis, flow chemistry technologies and peptide research and development. Almac Sciences has grown rapidly over the last 5 years with significant investments in its non-GMP and GMP manufacturing plants to support increased client manufacturing demands. Adding to this growth, the first phase of expansion for technology development has been completed with the opening of a new facility housing additional R&D scientists to develop new technology and projects for Almac’s established biocatalysis, flow chemistry and peptides businesses.  Additional capacity has also been created to enable further growth of its chemical development offering. The 2,000m2, two-storey dedicated…
World Encephalitis Day is the global awareness day for people who have been directly or indirectly affected by encephalitis. Founded by The Encephalitis Society in 2014, it is held on February 22 each year and has reached over 186 million people through media features, events and social media. It is our hope that it will play a leading role in our mission to increase global awareness of encephalitis and therefore saving lives and building better futures. For this year's Lights Camera Action campaign we are lighting up over 90 global landmarks around the world and encouraging supporters to go #Red4WED by wearing red on Monday, 22nd February, and telling people about why it is important more people know about encephalitis. Encephalitis Facts Encephalitis is inflammation of the brain – a dev…
Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases. Rigel's lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and will begin Phase 2 clinical trials in 2021 as part of the collaboration.  Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. Under the terms of the agreement, Li…
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “Cognate BioServices presents a unique opportunity to expand into a high-growth, value-added sector of the CDMO market and enhance our ability to meet our clients’ needs in emerging areas of scientific innovation. Th…
GSK has announced aspirational targets to make further progress on its gender and ethnic diversity representation in senior leadership. As a result of work to increase female representation in senior roles, GSK has already exceeded its target of 37% of VP-level and above roles being filled by women. The company will now extend this to increase female representation in VP level and above roles to at least 45% by 2025. To drive greater racial and ethnic diversity in senior roles in its two biggest employee populations in the US and UK, new targets have been introduced in these countries, reflecting demographics in these countries. In the US, a new target of at least 30% ethnically diverse leaders by the end of 2025 is now in place to increase representation from the current level of 23%. In…
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65. The authorisation of COVID-19 Vaccine AstraZeneca manufactured by AstraZeneca, and COVISHIELD manufactured by Serum Institute of India (SII), enables global access to the vaccine during the pandemic. The EUL allows for two doses of the vaccine to be administered at a four to 12-week interval. This regimen was shown in clinical trials to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose. The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended a do…
The University of Glasgow has entered into a research collaboration with pharmaceutical company Eli Lilly and Company, that aims to discover and validate the next generation of drug targets for immunological diseases. The £4.6million research collaboration, due to last four years, will work across four diseases – psoriatic arthritis, rheumatoid arthritis, fibrosis and vasculitis – and will be led by the University of Glasgow’s Institute of Infection, Immunity and Inflammation. The collaboration will allow scientists from UofG and Lilly to work together in order to drive the research forward – a move researchers hope will help enable the identification of first-in-class therapeutics for people suffering with these devastating and costly conditions. For instance, rheumatoid arthritis alone a…
The ABPI is delighted to announce that the ABPI Board has unanimously elected Ben Osborn, UK Country Manager, Pfizer, as President-elect of the ABPI. Ben has over twenty years of experience across a wide range of leadership roles at Pfizer, where he began his career in 1998. Prior to his appointment as UK Country Manager in 2018, Ben held the role of Chief Marketing Officer, Pfizer Innovative Health where he led the marketing organisation across Europe, Japan, Korea and ANZ. Ben will formally take over the ABPI Presidency from Haseeb Ahmad on 1 May, following our AGM on 30 April. Until then, Haseeb will remain ABPI President. Further information will follow, and Ben will be available for interview from May 1.
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, "off-the-shelf" CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T cells by the host immune system remains a key challenge to their broader development. Employing Caribou's CRISPR genome editing platform to engineer CAR-T cells to withstand host immune attack would enable the development of the next-generation of "off-the-shelf" cellular therapies to benefit a broader patient population.   Under the…
Continued partnership will enhance experience for customers and colleagues and help accelerate cloud innovation on next-generation network BT today announced a new, multi-year agreement with Walgreens Boots Alliance (WBA) to continue to be the company’s network partner in the UK and Republic of Ireland. Under the agreement, BT will work to transform WBA’s networking and enhance the customer and colleague experience with the deployment of next-generation technology.Steve Rempel, senior vice president and international chief information officer, WBA, said, “We chose BT because we share a focus on delivering standout customer experiences. Our digital plans demand full visibility, control and security of applications and data crossing our network so we can join up in-store and online experienc…